Evolution of biomarker qualification at the health authorities (original) (raw)

Nature Biotechnology volume 28, pages 441–443 (2010)Cite this article

Subjects

By streamlining the qualification process for biomarkers, coordinated protocols recently implemented at the different regulatory agencies can facilitate progress and provide impetus to novel biomarker discovery and validation.

This is a preview of subscription content, access via your institution

Access options

Subscribe to this journal

Receive 12 print issues and online access

$209.00 per year

only $17.42 per issue

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Additional access options:

References

  1. European Agency for the Evaluation of Medical Products. Public Statement: EU–US FDA Bilateral Agreement (EMEA, London, UK, 2003; accessed 8 September 2009). http://www.emea.europa.eu/pdfs/general/direct/pr/2447803en.pdf
  2. The Food and Drug Administration. Guidance for Industry: Pharmacogenomic Data Submissions (FDA, Rockville, Maryland, USA, March 2005; accessed 8 September 2009). http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm079849.pdf
  3. European Agency for the Evaluation of Medical Products. Medicines and Emerging Science (EMEA, London, UK, accessed 8 September 2009) http://www.emea.europa.eu/htms/human/mes/emergingtechnologies.htm
  4. The Food and Drug Administration. Fed. Reg. 69, 48876–48877 (2004). http://www.fda.gov/OHRMS/DOCKETS/98fr/04-18360.htm
  5. The European Medicines Agency. EMEA/CHMP/PGxWP/20227/04 Guideline on Pharmacognetics Briefing Meetings (EMEA, London, UK, 2004; accessed 8 September 2009). http://www.ema.europa.eu/pdfs/human/pharmacogenetics/2022704en.pdf
  6. Uyama, Y. Nippon Yakurigaku Zasshi 126, 432–435 (2005).
    PubMed Google Scholar
  7. The Food and Drug Administration. Critical Path Initiative (FDA, Rockville, Maryland, USA, (2004) http://www.fda.gov/ScienceResearch/SpecialTopics/CriticalPathInitiative/default.htm
  8. The European Medicines Agency. The European Medicines Agency Road Map to 2015: Preparing the Ground for the Future (EMEA, London, UK, 2010; 8 September 2009). http://www.emea.europa.eu/htms/general/direct/roadmap/roadmapintro.htm
  9. The European Medicines Agency. Innovative Drug Development Approaches (EMEA/127318/2007)—Final Report of the EMEA/CHMP Think-Tank on Innovative Drug Development (EMEA, London, UK, 2007; accessed 8 September 2009). http://www.ema.europa.eu/pdfs/human/itf/12731807en.pdf
  10. Goodsaid, F.M., Frueh, F.W. & Mattes, W. Toxicology. 245, 219–223 (2008).
    Article CAS Google Scholar
  11. Hunter, A.J. Drug Discov. Today. 13, 371–373 (2008).
    Article Google Scholar
  12. The European Medicines Agency. Final Report on the Pilot Joint EMEA/FDA VXDS Experience on Qualification of Nephrotoxicity Biomarkers (EMEA, London, UK, May 2008; accessed 8 September 2009). http://www.ema.europa.eu/pdfs/human/biomarkers/25088508en.pdf
  13. Altar, C.A. et al. Clin. Pharmacol. Ther. 83, 368–371 (2008).
    Article CAS Google Scholar
  14. Lathia, C.D. et al. Clin. Pharmacol. Ther. 86, 32–43 (2009).
    Article CAS Google Scholar
  15. The Food and Drug Administration. E16 Genomic Biomarkers Related to Drug Response: Context, Structure, and Format of Qualification Submissions (FDA, Rockville, Maryland, USA; accessed 8 September 2009). http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM174433.pdf
  16. The Food and Drug Administration. Fed. Reg. 69, 42060–42061 (2004; accessed 8 September 2009). http://www.fda.gov/OHRMS/DOCKETS/98fr/04-15935.htm
  17. The Food and Drug Administration. Table of Valid Genomic Biomarkers in the Context of Approved Drug Labels (FDA, Rockville, Maryland, USA; accessed 8 September 2009). http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm083378.htm.
  18. The European Medicines Agency. Guidance Document on the Qualification of Novel Methodologies for Drug Development (EMEA, London, UK, January 2009; accessed 8 September 2009). http://www.ema.europa.eu/pdfs/human/biomarkers/7289408en.pdf

Download references

Author information

Author notes

  1. Marisa Papaluca is at The European Medicines Agency, London, UK.

Authors and Affiliations

  1. Federico Goodsaid is at the Food and Drug Administration, Silver Spring, Maryland, USA, and,
    Federico Goodsaid & Marisa Papaluca

Authors

  1. Federico Goodsaid
    You can also search for this author inPubMed Google Scholar
  2. Marisa Papaluca
    You can also search for this author inPubMed Google Scholar

Corresponding authors

Correspondence toFederico Goodsaid or Marisa Papaluca.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

About this article

Cite this article

Goodsaid, F., Papaluca, M. Evolution of biomarker qualification at the health authorities.Nat Biotechnol 28, 441–443 (2010). https://doi.org/10.1038/nbt0510-441

Download citation

This article is cited by